Most researchers seeking out CJC-1295 in Sapol immediately realize that local retail options are essentially nonexistent. The benefit of this online-only market is that serious vendors are judged entirely by their analytical documentation, giving researchers more rigorous quality data than any local market ever offers. What reliably differentiates top CJC-1295 vendors is comprehensive lot-matched testing data: HPLC for purity, mass spec for peptide identity confirmation, and endotoxin testing for safety screening. What follows is a sourcing and quality evaluation guide built specifically around CJC-1295, covering everything a Sapol researcher needs to source confidently.
CJC-1295 Mechanisms Explained
CJC-1295 with DAC (Drug Affinity Complex) is a GHRH analogue with an extended half-life achieved through DAC technology that enables covalent binding to albumin. This modification extends the half-life from minutes (for native GHRH) to approximately 6-8 days, creating a sustained elevation in basal GH levels rather than the pulsatile pattern produced by GHRP compounds. This pharmacokinetic distinction is significant for research design: CJC-1295 based on CJC-1295 with DAC produces a different GH secretion pattern than GHRP compounds, with different downstream effects on IGF-1 and protein synthesis. Researchers in Sapol comparing compounds in this class should account for these pharmacokinetic differences in their experimental design.
Sourcing Research-Grade CJC-1295
Quality CJC-1295 sourcing begins with a straightforward question: does this vendor share complete COA data without being asked? Suppliers that publish proactively are signalling genuine quality commitment. The HPLC chromatogram is the most important document in the COA: it should show a clear dominant peak representing CJC-1295, with minimal secondary peaks representing impurities — purity should be stated as ≥98%. Negative indicators in CJC-1295 vendor evaluation: prices more than 30-40% below standard market rates, unclear production details, no community presence, and COAs that lack endotoxin data. Store lyophilised CJC-1295 at −20°C until ready to use; reconstitute only the volume needed for upcoming use and keep the remainder frozen.
Order CJC-1295 — ships to Sapol
COA-verified · International tracking · Research grade
CJC-1295 operates outside approved pharmaceutical regulation — researchers should understand that the safety data available for CJC-1295 is based on research literature rather than clinical trials. Storage requirements for CJC-1295: lyophilised powder at −20°C, reconstituted solution stored refrigerated at 2-8°C and consumed within 4 weeks; reconstitute only with bac water. Verify the endotoxin level in your CJC-1295 batch COA before any protocol involving administration — look for results reported in endotoxin units per mg or mL and verify they are within the acceptable range for your research context. The research literature on CJC-1295 should be read critically before designing any protocol — study methodologies, dosing, and endpoints vary significantly and not all findings translate directly.
Frequently Asked Questions
What is the difference between CJC-1295 with DAC and without DAC?
CJC-1295 with DAC uses a lysine-maleimide conjugate to bind covalently to albumin in the bloodstream, extending half-life to ~6-8 days and creating sustained GH elevation. CJC-1295 without DAC (also called Mod GRF 1-29) has a half-life of ~30 minutes and produces acute GH pulses. They produce different GH secretion patterns and have different applications in research.
What purity is required for CJC-1295 research?
CJC-1295 should be ≥98% pure by HPLC. The larger molecular weight of CJC-1295 with DAC (approximately 3647 Da) makes mass spectrometry confirmation particularly important, as impurities may not be obvious on HPLC alone.
What is CJC-1295?
CJC-1295 is a synthetic GHRH (Growth Hormone Releasing Hormone) analogue. The version with DAC (Drug Affinity Complex) has an extended half-life of approximately 6-8 days due to albumin binding. Without DAC, CJC-1295 has a much shorter half-life similar to native GHRH. Both versions stimulate pulsatile GH release via the GHRH receptor.
